ClinicalTrials.gg
Sign In
CompletedNCT03468036INNOVATEUpdated Jan 26, 2023

Intratracheal Suctioning and Oxygenation at Extubation

An observational study in Extubation, sponsored by Jörg Schefold. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.

Primary conditionCritical Illness(the registry's first term)UnverifiedIs this wrong?Critical Illness is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by Jörg Schefold · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Study summary

Data analysis of routinely applied extubation procedures on the ICU: i.e. extubation with 100% O2 vs. 35% O2 with/without suctioning.

02

Conditions studied

  • Extubation

Browse trials for

Keywords

  • critical illness
  • ICU
  • extubation
  • respiratory failure
03

In context

Critical Illness Unverified

1,780 studies on the registry are indexed under Critical Illness; 442 are open to participants now.

This study's enrollment of 250 is above the median of 140 across 814 observational studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

Jörg Schefold is the lead sponsor of 2 studies on the registry; none are open to participants now.

Compared within Critical Illness, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

ICU patients that undergo routine extubation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All adult (≥18 years) ICU patients with routine extubation on the ICU during the 2-month observational interval.

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Patients on comfort therapy and/ or terminal extubation or accidental extubationtracheostomized patients
  • Patients with refusal to general consent or withdrawal of general consent (DLF and/or internal database)
  • Patients dying without next-of-kin available
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
250 participants (actual)
Patient registry
No

Groups and cohorts

  • Extubation with 100% O2

    for further information please refer to study protocol

    Other: none, does not apply

  • Extubation with 35% O2

    for further information please refer to study protocol

    Other: none, does not apply

Interventions

  • Othernone, does not apply

    none: does not apply

06

What researchers measure

Primary outcomes

  1. Difference in proportion of patients with need for ongoing ventilatory support

    Time frame: 30 days max follow-up

07

Study locations

1 site
  • Dept. of Intensive Care Medicine, University of Bern,
    Bern, 3010, Switzerland
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Dec 2022, 37 months.

Of 439 non-industry observational studies under Critical Illness, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's 37 months is above that.

Counting every sponsor, half of 442 studies reached it within 23 months; a quarter within 12 and three quarters within 46.

Critical Illness covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2018
First posted
Mar 16, 2018
StartActual
Oct 7, 2019
Primary completionActual
Dec 1, 2022
CompletionActual
Dec 1, 2022
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03468036
Lead sponsor
Jörg Schefold
Responsible party
Jörg Schefold (Sponsor-investigator, Insel Gruppe AG, University Hospital Bern) — Sponsor-investigator
First posted
Mar 16, 2018
Start date
Oct 7, 2019
Primary completion
Dec 1, 2022
Completion
Dec 1, 2022
Last update
Jan 26, 2023

Study contacts

Joerg C Schefold, MD
principal investigator · Inselspital, University of Bern

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Critical Illness →

Other studies from this sponsor

Jörg Schefold

Start the discussion